We are contrasting Zymeworks Inc. (NYSE:ZYME) and Neurocrine Biosciences Inc. (NASDAQ:NBIX) on their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks Inc.	53.02M	9.65	36.56M	-0.35	0.00
Neurocrine Biosciences Inc.	451.24M	15.79	21.11M	0.18	435.91

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Zymeworks Inc. and Neurocrine Biosciences Inc.

Profitability

Table 2 provides Zymeworks Inc. and Neurocrine Biosciences Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Zymeworks Inc.	-68.96%	-9.2%	-8%
Neurocrine Biosciences Inc.	4.68%	5.1%	2.4%

Liquidity

The Current Ratio and Quick Ratio of Zymeworks Inc. are 6.4 and 6.4 respectively. Its competitor Neurocrine Biosciences Inc.’s Current Ratio is 8.4 and its Quick Ratio is 8.2. Neurocrine Biosciences Inc. can pay off short and long-term obligations better than Zymeworks Inc.

Analyst Ratings

In next table is shown Zymeworks Inc. and Neurocrine Biosciences Inc.’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Zymeworks Inc.	0	0	0	0.00
Neurocrine Biosciences Inc.	0	3	6	2.67

On the other hand, Neurocrine Biosciences Inc.’s potential upside is 38.66% and its average price target is $108.75.

Insider and Institutional Ownership

Zymeworks Inc. and Neurocrine Biosciences Inc. has shares owned by institutional investors as follows: 40.3% and 0%. Zymeworks Inc.’s share owned by insiders are 10.3%. Competitively, 1.2% are Neurocrine Biosciences Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Zymeworks Inc.	0.27%	-5.78%	11.19%	5.33%	44.04%	2.25%
Neurocrine Biosciences Inc.	-2.53%	-10.56%	-11.62%	-35.15%	-6.23%	10.49%

For the past year Zymeworks Inc. has weaker performance than Neurocrine Biosciences Inc.

Summary

Neurocrine Biosciences Inc. beats on 12 of the 12 factors Zymeworks Inc.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companyÂ’s lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Celgene Corporation and Celgene Alpine Investment Co. LLC, GlaxoSmithKline Intellectual Property Development Limited, and Daiichi Sankyo Co., Ltd. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company’s lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company’s research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL – Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.